← Back to Patent Explorer
US4201770A Expired / Lapsed US ⏱️ 0.0 years remaining

Antigenic modification of polypeptides

Assignee: The Ohio State University
•
Filing: 1978-08-25
•
Granted: 1980-05-06
•
Expires: 1998-08-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Modified hormones or fragments of hormones are useful in producing antibodies when administered to an animal. Said antibodies in turn cause neutralization of endogenous natural protein hormones. The modification may be accomplished by attaching various kinds of modifying groups to the hormone or fragment. Modification may, for example, be achieved by chemically coupling diazosulfanilic acid groups to the hormone or fragment. The protein hormones to which this procedure can be applied are mammalian protein reproductive hormones such as, for example, Follicle Stimulating Hormone (FSH), or Human Chorionic Gonadotropin (HGG). These modified hormone or fragment may be administered to animals for the purpose of contraception, abortion, or treatment of hormone related disease states and disorders.

Inventors

  • 👤 Vernon C. Stevens

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 16:28
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/59; A; A61; A61K; A61K39/00; A61K39/0005; A61K39/0006; A61K2039/555; A61K2039/55511; A61K2039/5555; A61K2039/60; A61K2039/6012; A61K38/00

Claims Analysis

Total Claims: 26
Claim 1
Independent Claim 122 words
A method for controlling fertility in primate animals having naturally occurring endogenous Chroionic Gonadotropin hormone by neutralizing the biological action of the endogenous hormone, comprising the steps of: administering to said primate animal an immunologically effective amount of the hormone, a subunit thereof, a peptide fragment of the subunit or a synthetically derived peptide having a sequence analogous to at least a portion of said subunit; said hormone, subunit, fragment or synthetically derived peptide being modified by the coupling thereof with a non-endogenous material to effect the formation, following said administration, of antibodies having a specificity to endogenous Chorionic Gonadotropin; thereby inhibiting the fertility of said primate animal by preventing one or more normal biological functions of the endogenous Chorionic Gonadotropin hormone.
Claim 2
Independent Claim 122 words
A method for controlling fertility in primate animals having naturally occurring endogenous Chroionic Gonadotropin hormone by neutralizing the biological action of the endogenous hormone, comprising the steps of: administering to said primate animal an immunologically effective amount of the hormone, a subunit thereof, a peptide fragment of the subunit or a synthetically derived peptide having a sequence analogous to at least a portion of said subunit; said hormone, subunit, fragment or synthetically derived peptide being modified by the coupling thereof with a non-endogenous material to effect the formation, following said administration, of antibodies having a specificity to endogenous Chorionic Gonadotropin; thereby inhibiting the fertility of said primate animal by preventing one or more normal biological functions of the endogenous Chorionic Gonadotropin hormone.
Claim 3
Dependent Claim 22 words
The method of claim 1 wherein said modified hormone, subunit, fragment or synthetically derived peptide is administered in combination with an adjuvant.
Claim 4
Independent Claim 112 words
The method of controlling fertility in primate animals having naturally occuring endogenous Chorionic Gonadotropin hormone comprising the steps of: providing a quantity of the hormone, a subunit thereof, a peptide fragment thereof, or a synthetically derived peptide having a sequence analogous to at least a portion of said subunit and being non-antigenic within said primate animals; modifying said hormone, subunit, fragment, or synthetically derived peptide by the coupling thereof with a non-endogenous material; administering to said primate animal an immunologically effective amount of said modified hormone, subunit, fragment, or synthetically derived peptide; thereby inhibiting the fertility of said primate animals by preventing one or more normal biological functions of endogenous Chorionic Gonadotropin.
Claim 5
Independent Claim 112 words
The method of controlling fertility in primate animals having naturally occuring endogenous Chorionic Gonadotropin hormone comprising the steps of: providing a quantity of the hormone, a subunit thereof, a peptide fragment thereof, or a synthetically derived peptide having a sequence analogous to at least a portion of said subunit and being non-antigenic within said primate animals; modifying said hormone, subunit, fragment, or synthetically derived peptide by the coupling thereof with a non-endogenous material; administering to said primate animal an immunologically effective amount of said modified hormone, subunit, fragment, or synthetically derived peptide; thereby inhibiting the fertility of said primate animals by preventing one or more normal biological functions of endogenous Chorionic Gonadotropin.
Claim 6
Dependent Claim 22 words
The method of claim 3 wherein said modified hormone, subunit, fragment or synthetically derived peptide is administered in combination with an adjuvant.
Claim 7
Dependent Claim 24 words
The method of claim 3 wherein said non-endogenous material is coupled with said hormone, subunit, fragment or synthetically derived peptide through a sulfhydryl-group linkage.
Claim 8
Dependent Claim 78 words
The method of claim 3 wherein said hormone, subunit, fragment or synthetically derived peptide is one having a sulfhydryl group therewithin, and said coupling is carried out by the treatment thereof with an activator of the structure ##STR10## wherein X represents a non-reacting connective entity so as to effect reaction of the maleiimide group of the activator with a said sulfhydryl group; and treating the resultant activated hormone, subunit, fragment or synthetically derived peptide with said non-endogenous material.
Claim 9
Dependent Claim 16 words
The method of claim 6 wherein said non-reacting connective entity, X, comprises an amino acid chain.
Claim 10
Dependent Claim 15 words
The method of claim 7 wherein said amino acid chain is a Prolene spacer chain.
Claim 11
Dependent Claim 14 words
The method of claim 3 wherein said non-endogenous material comprises sucrose copolymerized with epichlorohydrin.
Claim 12
Dependent Claim 18 words
The method of claim 3 wherein said non-endogenous material comprises (poly)tyrosine, (poly)alanine, (poly)dextran, thyroglobulin, or a combination thereof.
Claim 13
Dependent Claim 13 words
The method of claim 6 wherein said non-endogenous material comprises the protein, flagellin.
Claim 14
Dependent Claim 14 words
The method of claim 6 wherein said non-endogenous material material comprises an influenza virus.
Claim 15
Dependent Claim 23 words
The method of claim 12 in which said influenza virus is an influenza subunit incorporating substantially only the viral proteins Haemagglutin and Neuraminease.
Claim 16
Dependent Claim 12 words
The method of claim 6 wherein said non-endogenous material is diptheria toxiod.
Claim 17
Dependent Claim 13 words
The method of claim 6 wherein said non-endogenous material is a cholera organism.
Claim 18
Dependent Claim 25 words
The method of claim 6 wherein said activated hormone, subunit, fragment or synthetically derived peptide is treated with said non-endogenous material at slightly alkaline pH.
Claim 19
Dependent Claim 25 words
The method of claim 3 or 6 wherein said fragment which is modified is of the chemical configuration: Thr-Cys-Asp-Asp-Pro-Arg-Phe-Gln-Asp-Ser-Ser-Ser-Ser-Lys-Ala-Pro-Pro-Pro-Ser-Leu-Pro-Ser-Pro-Ser-Arg-Leu-Pro-Gly-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln; Asp-Asp-Pro-Arg-Phe-Gln-Asp-Ser-Pro-Pro-Pro-Cys-Pro-Pro-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln; Asp-Asp-Pro-Arg-Phe-Gln-Asp-Ser-Pro-Pro-Pro-Pro-Pro-Pro-Cys-Pro-Pro-Pro-Pro-Pro-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln; Asp-His-Pro-Leu-Thr-Aba-Asp-Asp-Pro-Arg-Phe-Gln-Asp-Ser-Ser-Ser-Ser-Lys-Als-Pro-Pro-Pro-Ser-Leu-Pro-Ser-Pro-Ser-Arg-Leu-Pro-Gly-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln-Pro-Pro-Pro-Pro-Pro-Pro-Cys; Asp-His-Pro-Leu-Thr-Aba-Asp-Asp-Pro-Arg-Phe-Gln-Asp-Ser-Ser-Ser-Ser-Lys-Ala-Pro-Pro-Pro-Ser-Leu-Pro-Ser-Pro-Ser-Arg-Leu-Pro-Gly-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln-Cys; or Cys-Pro-Pro-Pro-Pro-Pro-Pro-Asp-Asp-Pro-Arg-Phe-Gln-Asp-Ser-Ser-Ser-Ser-Lys-Ala-Pro-Pro-Pro-Ser-Leu-Pro-Ser-Pro-Ser-Arg-Leu-Pro-Gly-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln.
Claim 20
Dependent Claim 21 words
The method of claim 3 wherein said fragment which is modified is of the chemical configuration: Asp-Asp-Pro-Arg-Phe-Gln-Asp-Ser-Ser-Ser-Ser-Lys-Ala-Pro-Pro-Pro-Ser-Leu-Pro-Ser-Pro-Ser-Arg-Leu-Pro-Gly-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln; Gln-Asp-Ser-Ser-Ser-Ser-Lys-Ala-Pro-Pro-Pro-Ser-Leu-Pro-Ser-Pro-Ser-Arg-Leu-Pro-Gly-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln, Phe-Gln-Asp-Ser-Ser-Ser-Ser-Lys-Ala-Pro-Pro-Pro-Ser-Leu-Pro-Ser-Pro-Ser-Arg-Leu-Pro-Gly-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln; or Asp-Asp-Pro-Arg-Phe-Gln-Asp-Ser-Ser-Ser-Ser-Lys-Als-Pro-Pro-Pro-Ser-Leu-Pro-Ser.
Claim 21
Dependent Claim 72 words
The method of claim 3 wherein said non-endogenous material is one having an amino group and said coupling is carried out by activating said non-endogenous material with an activator of the structure: ##STR11## where X represents a non-reacting connective entity so as to effect reaction of the activator with said amino group; and treating the activated non-endogenous material with said hormone, subunit, fragment or synthetically derived peptide which has a sulfhydryl group.
Claim 22
Dependent Claim 16 words
The method of claim 19 wherein said activation is carried out under neutral or acid conditions.
Claim 23
Dependent Claim 32 words
The method of claim 3 wherein said modification is carried out to effect the constitution of two or more immunological determinants effective to elicit antibody response to the endogenous hormone, Chorionic Gonadotropin.
Claim 24
Dependent Claim 76 words
The method of claim 3 wherein: said fragment or synthetically derived peptide which is modified is of the chemical configuration: Cys-Pro-Pro-Pro-Pro-Pro-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln and said administration thereof is in combination with another, different modified Chorionic Gonadotropin hormine, subunit thereof, peptide fragment of the said subunit, or a synthetically derived peptide having a sequence at least analogous to at least a portion of the fragment, the said modification of which effects the constitution of at least one immunological determinant.
Claim 25
Dependent Claim 76 words
The method of claim 3 wherein: said fragment or synthetically derived peptide which is modified is of the chemical configuration: Asp-Asp-Pro-Arg-Phe-Gln-Asp-Ser-Pro-Pro-Pro-Pro-Pro-Pro-Cys and said administration thereof is in combination with another, different modified Chorionic Gonadotropin hormine, subunit thereof, peptide fragment of the said subunit, or a synthetically derived peptide having a sequence at least analogous to at least a portion of the fragment, the said modification of which effects the constitution of at least one immunological determinant.
Claim 26
Dependent Claim 17 words
The method of claim 1 wherein said animal is human and said hormone is human Chorionic Gonadoptropin.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1983-05-06 1983-11-05 1984-05-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1987-05-06 1987-11-05 1988-05-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1991-05-06 1991-11-05 1992-05-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag